Efficacy and safety of intravitreal dexamethasone implant in patients with diabetic macular edema

Ophthalmologica

Volumn 233, Issue , 2015, Pages 169-175

  Guigou, Sebastien ^a   Pommier, Stephan ^a   Meyer, Franck ^a   Hajjar, Christian ^a   Merite, Pierre Yves ^a   Parrat, Eric ^a   Rouhette, Herve ^a   Rebollo, Olivier ^a   Matonti, Frederic ^a,b,c  

^a P15 Network ^*  (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c AIX MARSEILLE UNIVERSITÉ   (France)

Author keywords

Diabetes; Diabetic macular edema; Intravitreal dexamethasone implant; Optical coherence tomography; Ozurdex

Indexed keywords

DEXAMETHASONE; ANTIHYPERTENSIVE AGENT; DRUG IMPLANT; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; CATARACT; CENTRAL RETINAL THICKNESS; CONJUNCTIVAL HEMORRHAGE; DIABETIC MACULAR EDEMA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; INTRAVITREAL IMPLANT; MAJOR CLINICAL STUDY; MALE; MUSCLE HYPERTONIA; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VISUAL ACUITY; CLINICAL TRIAL; DIABETIC RETINOPATHY; DRUG EFFECTS; DRUG IMPLANT; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DEXAMETHASONE; DIABETIC RETINOPATHY; DRUG IMPLANTS; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETINA; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84930925386     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000381356     Document Type: Article

References (17)

1. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
2. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
3. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, Sutter F, Simader C, Burian G, Gerstner O, Weichselberger A; RESTORE Study Group: The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615-625.
4. Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, Tolentino M, Gupta A, Duarte L, Madreperla S, Gonder J, Kapik B, Billman K, Kane FE; FAME Study Group: Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011; 118: 626-635.
5. Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM; Ozurdex MEAD Study Group: Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014; 121: 1904-1914.
6. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL 3rd, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK; Diabetic Retinopathy Clinical Research Network: Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117: 1064-1077.
7. Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group: Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010; 128: 289-296.
8. Dutra Medeiros M, Postorino M, Navarro R, Garcia-Arumi J, Mateo C, Corcostegui B: Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema. Ophthalmologica 2014; 231: 141-146.
9. Matonti F, Meyer F, Guigou S, Barthelemy T, Dumas S, Gobert F, Hajjar C, Merite PY, Parrat E, Rouhette H, Pommier S: Ozurdex in the management of the macular edema following retinal vein occlusion in clinical practice. Acta Ophthalmol 2013; 91: 584-586.
10. Gillies MC, Lim LL, Campain A, Quin GJ, Salem W, Li J, Goodwin S, Aroney C, McAllister IL, Fraser-Bell S: A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: The BEVORDEX study. Ophthalmology 2014; 121: 2473-2481.
11. Sorkin N, Loewenstein A, Habot-Wilner Z, Goldstein M: Intravitreal dexamethasone implant in patients with persistent macular edema of variable etiologies. Ophthalmologica 2014; 232: 83-91.
12. Zucchiatti I, Lattanzio R, Querques G, Querques L, Del Turco C, Cascavilla ML, Bandello F: Intravitreal dexamethasone implant in patients with persistent diabetic macular edema. Ophthalmologica 2012; 228: 117-122.
13. Scaramuzzi M, Querques G, Spina C, Lattanzio R, Bandello F: Repeated intravitreal dexamethasone implant (Ozurdex) for diabetic macular edema. Retina 2015, Epub ahead of print.
14. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group: Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012; 119: 1388-1398.
15. Medeiros MD, Alkabes M, Navarro R, Garcia-Arumi J, Mateo C, Corcostegui B: Dexamethasone intravitreal implant in vitrectomized versus nonvitrectomized eyes for treatment of patients with persistent diabetic macular edema. J Ocul Pharmacol Ther 2014; 30: 709-716.
16. Torriglia A, Valamanesh F, Behar-Cohen F: On the retinal toxicity of intraocular glucocorticoids. Biochem Pharmacol 2010; 80: 1878-1886.
17. Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ, Fine SL, Blodi B, Klein ML, Martin AA, Hagstrom SA, Martin DF; CATT Research Group: Risk of geographic atrophy in the comparison of agerelated macular degeneration treatments trials. Ophthalmology 2014; 121: 150-161.